Haɓaka Tsarin Ci gaban Magunguna

Gabatarwa

Dangane da Fasaha da Sabis na zamani

Cikakken Bayani

Tags samfurin

Janar bayani

Fayil na farko da mafi kyawun aji an tsara shi don magance mahimman buƙatun likitanci waɗanda ba a cika su ba ta hanyar haɓaka nau'ikan jiyya na nau'ikan furotin guda biyu da ƙayyadaddun furotin, haɗin magungunan rigakafin ƙwayoyin cuta da macrophage masu haɓakawa ga marasa lafiya a duk duniya.

Tarihi

Binciken da Kohler da Milstein da Kohler da Milstein suka yi na fasaha mai karewa a ƙasa a cikin 1975 ya ba da damar ƙirƙirar ƙwayoyin rigakafi a matsayin nau'in maganin warkewa (Kohler & Milstein, 1975).Monoclonal antibodies (mAbs) ɗaya ne daga cikin hanyoyin da aka fi amfani da su na magunguna don cututtuka masu yaduwa ko maganin ciwon daji saboda suna zaɓen ƙwayoyin cuta, ƙwayoyin cuta, ƙwayoyin cuta, har ma da ƙwayoyin rigakafi.Ta wannan hanyar, suna yin sulhu don kawar da kwayoyin da aka yi niyya da sel tare da ƙarancin illa fiye da sauran hanyoyin warkewa.Musamman, mAbs na warkewa na kansa na iya gane sunadaran-tsarin sel akan ƙwayoyin da aka yi niyya sannan su kashe ƙwayoyin da aka yi niyya ta hanyoyi da yawa.
Halin ɗan adam yana rage yawan rigakafi na maganin warkewa a cikin ɗan adam, yana mai da yiwuwar gudanar da aiki na yau da kullun.Irin wannan ci gaban fasahar rigakafin mutum ya haifar da fashewa a cikin haɓakar mAbs na warkewa a cikin shekaru goma da suka gabata.Jerin abubuwan da suka samo asali, waɗanda suka haɗa da sunadaran Fc-fusion, magungunan antibody-drug conjugates (ADCs), immunocytokines (antibody-cytokine fusions), da antibody-enzyme fusions, kuma an haɓaka su kuma an daidaita su azaman sabon magani.

Tasirin kwayoyi

Ga marasa lafiya, sabbin magungunan da aka yi niyya suna nufin ƙarancin sakamako masu illa, ƙarancin asibiti, ingantacciyar rayuwa, haɓaka aiki, da mahimmanci, tsawaita rayuwa.Amma ci gaban miyagun ƙwayoyi yana da tsayi, tsari mai rikitarwa.

Magana

Kohler G, Milstein C. Ci gaba da al'adu na gaurayawan sel masu ɓoye antibody na takamaiman takamaiman.Yanayi.1975;256:495–497.doi: 10.1038/256495a0
Ecker DM, Jones SD, Levine HL.Therapeutic monoclonal antibody kasuwa.MAbs.2015; 7:9–14.doi: 10.4161/19420862.2015.989042.
Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics.Biosci Wakili 2015; 35 (4): e00225.An buga 2015 Jul 14. Akwai a https://pubmed.ncbi.nlm.nih.gov/26182432/.An shiga Yuli 2020.
Reichert, JM, da Valge-Archer, VE (2007).Hanyoyin haɓaka don maganin ciwon daji na monoclonal antibody.Nat Rev Drug Discov 6, 349-356.
Lazar, GA, Dang, W., Karki, S., Vafa, O., Peng, JS, Hyun, L., Chan, C., Chung, HS, Eivazi, A., Yoder, SC, et al.(2006).bambance-bambancen antibody Fc na injiniya tare da ingantaccen aikin mai tasiri.PNAS 103, 4005-4010.


  • Na baya:
  • Na gaba:

  • Ku rubuta sakonku anan ku aiko mana

    Kwararren injiniyan fasaha da aka sadaukar don jagorantar ku

    Dangane da ainihin bukatun ku, zaɓi mafi madaidaicin ƙira da hanyoyin tsarawa gabaɗaya